Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics

Regeneron Pharmaceuticals, Inc. (REGN)

Today's Latest Price: $400.66 USD

0.15 (-0.04%)

Updated Feb 20 10:08am

Add REGN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

REGN Stock Summary

  • REGN has a market capitalization of $42,902,694,783 -- more than approximately 94.88% of US stocks.
  • REGN's went public 28.9 years ago, making it older than 82.85% of listed US stocks we're tracking.
  • REGN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 17.49% of US stocks.
  • Stocks that are quantitatively similar to REGN, based on their financial statements, market capitalization, and price volatility, are LRCX, XLNX, AMAT, RACE, and CDNS.
  • Visit REGN's SEC page to see the company's official filings. To visit the company's web site, go to
REGN Daily Price Range
REGN 52-Week Price Range

REGN Stock Price Chart More Charts

REGN Price/Volume Stats

Current price $400.66 52-week high $442.00
Prev. close $400.81 52-week low $271.37
Day low $396.00 Volume 83,284
Day high $401.08 Avg. volume 809,497
50-day MA $373.59 Dividend yield N/A
200-day MA $324.75 Market Cap 44.08B

Regeneron Pharmaceuticals, Inc. (REGN) Company Bio

Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.

REGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Regeneron Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 65st percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 43.67% on a DCF basis. The most interesting components of our discounted cash flow analysis for Regeneron Pharmaceuticals Inc ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is 81.43 -- which is good for besting 91.43% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately only 8.71% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 59.51% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as REGN, try OSMT, HUM, OMI, PDEX, and GILD.

REGN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

REGN Latest Social Stream

Loading social stream, please wait...

View Full REGN Social Stream

REGN Price Returns

1-mo 10.16%
3-mo 11.09%
6-mo 39.68%
1-year -5.17%
3-year 7.94%
5-year -5.46%
YTD 6.71%
2019 0.53%
2018 -0.65%
2017 2.42%
2016 -32.38%
2015 32.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7131 seconds.